Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group

L. P. Miller, A. F. Pyesmany, Lawrence Wolff, P. C J Rogers, S. E. Siegel, R. J. Wells, J. D. Buckley, G. D. Hammond

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7. Maintenance therapy consisted of IV etoposide (VP-16) (100 mg/m2) for 5 days and IV AMSA (100 mg/m2) on day 1. Of 122 patients, 109 were evaluable. There were 13 early deaths. Ninety-six patients received adequate therapy defined as completion of two courses of therapy. Of these 96 patients, 52 achieved complete remission. Fifteen of 33 patients who failed initial induction achieved complete remission. Eighteen of 39 patients who were resistant to anthracyclines had complete responses. There was no direct evidence of AMSA-induced cardiotoxicity. Remission duration was 28 days to 3 or more years (median, 98 days). AMSA and cyclocytidine were effective retrieval therapy for patients who were in relapse or unresponsive to frontline therapy. Duration of remission was short (median, 98 days).

Original languageEnglish (US)
Pages (from-to)2235-2240
Number of pages6
JournalCancer
Volume67
Issue number9
StatePublished - 1991

Fingerprint

Ancitabine
Amsacrine
Acute Myeloid Leukemia
Neoplasms
Etoposide
Therapeutics
Recurrence
Anthracyclines
Pediatrics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miller, L. P., Pyesmany, A. F., Wolff, L., Rogers, P. C. J., Siegel, S. E., Wells, R. J., ... Hammond, G. D. (1991). Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. Cancer, 67(9), 2235-2240.

Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. / Miller, L. P.; Pyesmany, A. F.; Wolff, Lawrence; Rogers, P. C J; Siegel, S. E.; Wells, R. J.; Buckley, J. D.; Hammond, G. D.

In: Cancer, Vol. 67, No. 9, 1991, p. 2235-2240.

Research output: Contribution to journalArticle

Miller, LP, Pyesmany, AF, Wolff, L, Rogers, PCJ, Siegel, SE, Wells, RJ, Buckley, JD & Hammond, GD 1991, 'Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group', Cancer, vol. 67, no. 9, pp. 2235-2240.
Miller, L. P. ; Pyesmany, A. F. ; Wolff, Lawrence ; Rogers, P. C J ; Siegel, S. E. ; Wells, R. J. ; Buckley, J. D. ; Hammond, G. D. / Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. In: Cancer. 1991 ; Vol. 67, No. 9. pp. 2235-2240.
@article{96954951ffcf4e75aadb3a4d2d59d0d0,
title = "Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group",
abstract = "Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7. Maintenance therapy consisted of IV etoposide (VP-16) (100 mg/m2) for 5 days and IV AMSA (100 mg/m2) on day 1. Of 122 patients, 109 were evaluable. There were 13 early deaths. Ninety-six patients received adequate therapy defined as completion of two courses of therapy. Of these 96 patients, 52 achieved complete remission. Fifteen of 33 patients who failed initial induction achieved complete remission. Eighteen of 39 patients who were resistant to anthracyclines had complete responses. There was no direct evidence of AMSA-induced cardiotoxicity. Remission duration was 28 days to 3 or more years (median, 98 days). AMSA and cyclocytidine were effective retrieval therapy for patients who were in relapse or unresponsive to frontline therapy. Duration of remission was short (median, 98 days).",
author = "Miller, {L. P.} and Pyesmany, {A. F.} and Lawrence Wolff and Rogers, {P. C J} and Siegel, {S. E.} and Wells, {R. J.} and Buckley, {J. D.} and Hammond, {G. D.}",
year = "1991",
language = "English (US)",
volume = "67",
pages = "2235--2240",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group

AU - Miller, L. P.

AU - Pyesmany, A. F.

AU - Wolff, Lawrence

AU - Rogers, P. C J

AU - Siegel, S. E.

AU - Wells, R. J.

AU - Buckley, J. D.

AU - Hammond, G. D.

PY - 1991

Y1 - 1991

N2 - Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7. Maintenance therapy consisted of IV etoposide (VP-16) (100 mg/m2) for 5 days and IV AMSA (100 mg/m2) on day 1. Of 122 patients, 109 were evaluable. There were 13 early deaths. Ninety-six patients received adequate therapy defined as completion of two courses of therapy. Of these 96 patients, 52 achieved complete remission. Fifteen of 33 patients who failed initial induction achieved complete remission. Eighteen of 39 patients who were resistant to anthracyclines had complete responses. There was no direct evidence of AMSA-induced cardiotoxicity. Remission duration was 28 days to 3 or more years (median, 98 days). AMSA and cyclocytidine were effective retrieval therapy for patients who were in relapse or unresponsive to frontline therapy. Duration of remission was short (median, 98 days).

AB - Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7. Maintenance therapy consisted of IV etoposide (VP-16) (100 mg/m2) for 5 days and IV AMSA (100 mg/m2) on day 1. Of 122 patients, 109 were evaluable. There were 13 early deaths. Ninety-six patients received adequate therapy defined as completion of two courses of therapy. Of these 96 patients, 52 achieved complete remission. Fifteen of 33 patients who failed initial induction achieved complete remission. Eighteen of 39 patients who were resistant to anthracyclines had complete responses. There was no direct evidence of AMSA-induced cardiotoxicity. Remission duration was 28 days to 3 or more years (median, 98 days). AMSA and cyclocytidine were effective retrieval therapy for patients who were in relapse or unresponsive to frontline therapy. Duration of remission was short (median, 98 days).

UR - http://www.scopus.com/inward/record.url?scp=0026360043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026360043&partnerID=8YFLogxK

M3 - Article

C2 - 1707336

AN - SCOPUS:0026360043

VL - 67

SP - 2235

EP - 2240

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -